 | | Vol. 5.39 – 22 October, 2021 |
| |
|
|
| Scientists reported that glycogen accumulation was a key initiating oncogenic event during liver malignant transformation, and found that glucose-6-phosphatase catalyzing the last step of glycogenolysis was frequently downregulated to augment glucose storage in pre-malignant cells.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| To identify a protease signature of nonalcoholic steatohepatitis (NASH), a transcriptomic analysis of 355 human liver biopsies was performed and identified a 13-protease panel that discriminated clinically relevant NASH ≥F2 fibrosis from F0-F1 with high classification accuracy across two independent patient datasets.
[Science Translational Medicine] |
|
|
|
| Researchers showed that human hepatic organoids, engineered to express the most common causative mutation for autosomal recessive polycystic kidney disease (ARPKD), developed the key features of ARPKD liver pathology in only 21 days.
[Nature Communications] |
|
|
|
| In multiple hepatocellular carcinoma patient-derived organoids and human tumor xenograft models, the drug combination of ifenprodil synergized with sorafenib, but neither single drug alone, markedly reduced tumor-initiating cancer cell frequency.
[Cancer Research] |
|
|
|
| Numb silencing in cultured intrahepatic cholangiocarcinoma cells enhanced cell spheroid growth, invasion, metastasis, and the expression of stem cell markers.
[Cell Death & Disease] |
|
|
|
| Centrosomal P4.1-associated protein (CPAP) increased the expression of chemokine ligand 16 (CCL-16), an important chemotactic cytokine, in human hepatocytes. CCL-16 expression was positively correlated with CPAP and TNF-α mRNA expression in the peritumoral part of hepatocellular carcinoma.
[Cell Death & Disease] |
|
|
|
| Scientists investigated whether fibroblast growth factor 21 (FGF21) was involved in the therapeutic effect of sulforaphane against non-alcoholic fatty liver disease.
[Acta Pharmacologica Sinica] |
|
|
|
| Investigators optimized the in vitro liver fibrotic niches and subsequently harvested their bioactive ingredients as niche extracts
[iScience] |
|
|
|
| Scientists investigated whether growth differentiation factor-15 (GDF-15) concentrations were associated with liver fibrosis and involved in the relationship between type 2 diabetes mellitus (T2DM) and liver fibrosis, as well as what factors linked with T2DM were associated with increased GDF-15 concentrations.
[Nutrition & Diabetes] |
|
|
|
| Researchers found that RCN1, an endoplasmic reticulum resident protein, was significantly upregulated in sorafenib-resistant hepatocellular carcinoma cells and promoted tumor progression.
[Cell Death Discovery] |
|
|
|
| The authors reported the successful generation of 3D thermally crosslinked preforms by using solution blow spinning (SBS) from porcine gelatin. They then used SBS mats as culturing substrates for human hepatocytes to create an array of 3D human liver tissue equivalents in 96-well format.
[Scientific Reports] |
|
|
|
| Lesogaberan’s potential efficacy in non-alcoholic steatohepatitis (NASH) was tested in human stellate cells, human precision cut liver slices, and in vivo in a well-validated murine model of NASH.
[Scientific Reports] |
|
|
|
| Researchers proved that estrogen had a protective effect on both hepatocyte hypoxia re-oxygen challenge and mouse hepatic ischemia reperfusion model.
[Journal of Physiology and Biochemistry] |
|
|
|
|
| The authors review proposed mutations in the recipient embryo to disable hepatogenesis, and discuss the advantages of using fumarylacetoacetate hydrolase knockouts and other genetic modifications to disable hepatogenesis.
[Stem Cell Reports] |
|
|
|
| Scientists summarize the available evidence on the microbiome environment in patients with biliary tract cancer, including a discussion around confounding factors, implications for therapy and proposed future directions.
[British Journal of Cancer] |
|
|
|
| Investigators describe strategies for establishing primary hepatocyte organoids derived from either adult or fetal liver based on insights from signaling pathways regulating hepatocyte renewal in vivo.
[Experimental & Molecular Medicine] |
|
|
|
|
| Oncodesign and TiumBio have announced the signature of a research collaboration agreement on R&D of potential drug candidates for fibrosis. Under this agreement, Oncodesign will be responsible for identification, chemical synthesis and optimization of Nanocyclix® drug candidates and their early-stage analysis.
[Oncodesign] |
|
|
|
| Seal Rock Therapeutics, Inc. announced completion of the single ascending dose portion of its Phase I clinical trial of SRT-015, a next-generation, liver-selective inhibitor of Apoptosis Signal-regulating Kinase 1 for non-alcoholic steatohepatitis (NASH) and other liver diseases such as alcoholic hepatitis.
[Seal Rock Therapeutics, Inc.] |
|
|
|
|
| November 9 – 10, 2021
Montpellier, France |
|
|
|
|
|
| | Gordian Biotechnology – San Francisco, California, United States |
|
|
|
| | Genome Institute of Singapore – Singapore, Singapore |
|
|
|
| | National Institutes of Health – Bethesda, Maryland, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | Novo Nordisk – Indianapolis, Indiana, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
